Interdisciplinary periprocedural management of patients undergoing transapical tmvi with the tendyne™ system: A narrative review and institutional experience.
Options
BORIS DOI
Publisher DOI
PubMed ID
40811142
Description
Objectives
Mitral regurgitation (MR) represents the most common valvular heart disease (VHD) in the Western world. While transcatheter mitral valve repair (M-TEER) is the leading interventional treatment for surgically high-risk patients, transcatheter mitral valve implantation (TMVI) is reserved for selected patients with unsuitable anatomy for M-TEER. This review aims to summarize our institutional experience with TMVI using the Tendyne™ valve (Abbott Vascular, CA, USA), focusing on interdisciplinary preoperative, intraoperative, and postoperative management strategies.Methods
We conducted a narrative review of current literature on TMVI with the Tendyne™ system and integrated it with a comprehensive analysis of our interdisciplinary clinical experience. Data were collected regarding patient selection, imaging protocols, procedural techniques, and postoperative care.Results
Utilizing the Tendyne™ valve, TMVI addresses symptomatic moderate-to-severe or severe MR in patients unsuitable for conventional surgery or transcatheter mitral valve repair (M-TEER). Successful outcomes require thorough patient selection, including assessment for minimal mitral annular calcification, absence of intracardiac thrombus, low left ventricular outflow tract (LVOT) obstruction risk, and optimal annular sizing. Multimodal imaging, particularly transoesophageal echocardiography and cardiac computed tomography, is essential for procedural planning and execution. TMVI is performed under general anaesthesia with intraoperative transoesophageal guidance and haemodynamic monitoring to minimize complications such as LVOT obstruction, bleeding, and valve malposition. Postoperative management emphasizes haemodynamic stabilization, bleeding control, and surveillance for paravalvular leaks or device dysfunction.Conclusions
TMVI with the Tendyne™ valve provides a viable and effective treatment for selected patients with symptomatic moderate to severe MR. Optimal outcomes are dependent on meticulous interdisciplinary collaboration, advanced imaging protocols, and comprehensive perioperative management.
Mitral regurgitation (MR) represents the most common valvular heart disease (VHD) in the Western world. While transcatheter mitral valve repair (M-TEER) is the leading interventional treatment for surgically high-risk patients, transcatheter mitral valve implantation (TMVI) is reserved for selected patients with unsuitable anatomy for M-TEER. This review aims to summarize our institutional experience with TMVI using the Tendyne™ valve (Abbott Vascular, CA, USA), focusing on interdisciplinary preoperative, intraoperative, and postoperative management strategies.Methods
We conducted a narrative review of current literature on TMVI with the Tendyne™ system and integrated it with a comprehensive analysis of our interdisciplinary clinical experience. Data were collected regarding patient selection, imaging protocols, procedural techniques, and postoperative care.Results
Utilizing the Tendyne™ valve, TMVI addresses symptomatic moderate-to-severe or severe MR in patients unsuitable for conventional surgery or transcatheter mitral valve repair (M-TEER). Successful outcomes require thorough patient selection, including assessment for minimal mitral annular calcification, absence of intracardiac thrombus, low left ventricular outflow tract (LVOT) obstruction risk, and optimal annular sizing. Multimodal imaging, particularly transoesophageal echocardiography and cardiac computed tomography, is essential for procedural planning and execution. TMVI is performed under general anaesthesia with intraoperative transoesophageal guidance and haemodynamic monitoring to minimize complications such as LVOT obstruction, bleeding, and valve malposition. Postoperative management emphasizes haemodynamic stabilization, bleeding control, and surveillance for paravalvular leaks or device dysfunction.Conclusions
TMVI with the Tendyne™ valve provides a viable and effective treatment for selected patients with symptomatic moderate to severe MR. Optimal outcomes are dependent on meticulous interdisciplinary collaboration, advanced imaging protocols, and comprehensive perioperative management.
Date of Publication
2025-11-06
Publication Type
Article
Subject(s)
Language(s)
en
Contributor(s)
Series
Interdisciplinary cardiovascular and thoracic surgery
Publisher
Oxford University Press
ISSN
2753-670X
Access(Rights)
open.access